Key Highlights

  • Dror Ortho-Design Penny Stock shareholders approved a Reverse Stock Split at a special meeting, with an exceptionally wide permitted range of 1-for-2 to 1-for-2,000.
  • The board must implement the split, at a ratio of its choosing, before the first anniversary of Shareholder approval, meaning by September 2027.
  • The company had 976,997,116 common shares and 5,847,937 Series A Preferred Shares outstanding, with preferred stock carrying a disproportionately large share of total voting power.
  • The company has not stated its reason for the split or whether it intends to pursue a listing on a major exchange such as Nasdaq.

Dror Ortho-Design, Inc. (OTC:DROR), a Jerusalem-based developer of teeth-straightening technology, reported that its stockholders approved a reverse stock split at a special meeting, granting the board authority to combine shares at any ratio between 1-for-2 and 1-for-2,000, with the exact ratio left to the board's discretion. The proposal passed with 707,862,992.08 votes for and 1,451,900 against, with no abstentions recorded.

The company had 976,997,116 common shares outstanding and 5,847,937 Series A preferred shares, which together carry 584,793,700 votes, meaning the preferred stock controls a very large block of voting power relative to its share count. The board must choose the exact ratio and implement the split before the first anniversary of the stockholder approval, meaning by September 2027, with the ratio to be announced publicly.

Latest Developments

A reverse split combines existing shares into fewer, higher-priced shares; at 1-for-2,000, a holder of 2,000 shares would end up with one, though the company's total Market Value and each investor's percentage stake do not change, apart from rounding of fractional shares. Companies usually pursue reverse splits to lift a very low share price, often to qualify for a major exchange listing or to tidy up a large share count before raising money, though Dror's filing does not state its reason and the company has not said whether it intends to seek an exchange listing.

The size of the permitted range stands out: a ceiling of 1-for-2,000 is far wider than most reverse split authorizations, and at the top end would cut nearly 977 million common shares to fewer than half a million. Wide ranges give a board flexibility, but they also leave shareholders uncertain about the ultimate outcome until an exact ratio is announced.

Financial and Business Position

Dror Ortho-Design was formerly Novint Technologies and adopted its current name in September 2023, headquartered in Jerusalem with a very small workforce. The company is developing ZSmile, an orthodontic platform it says straightens teeth using a smart appliance worn at night and a pulsating air mechanism, instead of aligners worn throughout the day, paired with a smartphone app and an AI-driven cloud service for treatment planning.

In January 2026, the company said Israel's Ministry of Health had approved ZSmile for Marketing in Israel, with a launch planned for 2026, and it is also pursuing clearance from the U.S. FDA and under European Union medical device regulations. CEO Lee Haddad called the Israeli approval a critical milestone. The clear aligner market is dominated by large, established players, so any small company entering it faces a heavy lift on marketing, clinician adoption and regulatory approvals outside its home market.

Stock-Market Context

Reverse splits in small companies often precede new share issuance, since a smaller share count leaves more room under the authorized share limit, though that is a general pattern rather than something Dror has announced. Approving a range does not force the company to act; the board could choose a modest ratio, or none at all, before the authority lapses in September 2027.

Waiting on the Board's Chosen Ratio

Investors are watching for the board's eventual choice of ratio and effective date, any move to apply for a Nasdaq or NYSE American listing that would help explain the split, potential share sales or Capital raises following the split, and continued regulatory progress on the ZSmile launch in Israel and any FDA submission, which will matter far more to the company's long-term value than the split itself.